VTVT

vTv Therapeutics Inc. Class A Common Stock (VTVT) | Rumor.io

vTv Therapeutics

VTVT

Attention (50-day avg)0%

Attention rank (50-day avg)#4,068

Bullish sentiment (50-day avg)100%

Price to earnings ratio-9.55

Market capitalization120.7M

Earnings per share-0.75

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-31.1M

Social

What share of all stock conversation is about VTVT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Jul 16

BTIG raises target price for VTVT to $57 from $49.
Volume is decent, but it's unclear whether the buying or selling is bullish.
The stock has been making money for some through shorting, but the lack of news is a gamble.

Generated by AI

Sentiment

Of the messages about VTVT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	94.36% -1.84
Bearish	—	—	0% 0	5.64% +1.84

Bullish· Mar 17

The low float of 1.2 million shares and strong recent news could drive $VTVT to $50.00.
$VTVT has shown a significant premarket move and strong volume increase, with a 2921% rise in volume compared to its daily average.
The stock has a strong technical setup, with a golden cross and potential for a breakout to $56, with many analysts and institutions owning a large portion of the shares.

Bearish· Jan 26

$VTVT is a potential victim of pump and dump scams, with coordinated scammers spreading fake posts to manipulate prices.
The stock's recent price action may be due to a rug pull, with the volume not supporting the alleged bull run.
$VTVT is considered a not wise investment, with many users warning against it and predicting a significant price drop.

Generated by AI

Topics

Of the messages about VTVT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	39.37%
Announcements	—	—	—	23.62%
Analysts	—	—	—	33.86%
Controversies	—	—	—	3.15%
Earnings	—	—	—	0%
Macro	—	—	—	0%

Earnings· May 10

$VTVT's earnings call is anticipated, but the exact date is not specified.
vTv Therapeutics Inc. had a mixed performance in December, but had previously surprised with three quarters of strong earnings.
vTv Therapeutics Inc.'s recent earnings have been a subject of optimism, with hopes for a strong showing in the latest report.

Analysts· Feb 18

Cantor Fitzgerald analyst Charles Duncan initiates coverage on vTv Therapeutics with an Overweight rating and a price target of $5.
The price target represents a significant premium to the current price, with a potential upside of 515.31%.
The analyst's enthusiasm is driven by vTv Therapeutics' lead candidate, ttp-399 (GK Activator), which is expected to enter Phase 3 trials soon as a potential treatment for Type-1 Diabetes.

Announcements· Mar 17

vTv Therapeutics' cadisegliatin program, including the CATT1 Phase 3 trial in type 1 diabetes, has been cleared by the FDA to resume after a clinical hold was lifted.
The hold was originally placed due to a chromatographic signal in a human absorption study, but was resolved as an experimental artifact after further investigation.
The company expects to expedite the initiation of pivotal studies for future New Drug Application submission by shortening the trial from 12 to 6 months.

Technical Analysis· Jun 1

$VTVT is building higher lows and may break $1, with a bullish trend line holding.
$VTVT has resistance near $1.05, $1.11, $1.19, $1.27, $1.37, $1.46, and $1.59, with support near $0.93, $0.85, and $0.78.
$VTVT needs to break above its vwap of $0.8337 for confirmation, and is testing a support level.

Generated by AI

Community

Of the messages about VTVT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	83.33%	71.92%
Newcomers	0%	0%	16.67%	28.08%

Regulars· Feb 28

The company vTv Therapeutics Inc. has secured a private placement of $51 million from healthcare-focused institutional investors and the JDRF T1D Fund.
This investment marks a significant milestone for the company, which has seen a notable increase in value, with a 55.2% pre-market rise.
The funds will support the company's ongoing efforts, particularly in the area of developing treatments for Type 1 diabetes.

Newcomers· Feb 28

New investors are watching $VTVT for its impressive price surge, up over 100% after announcing a $51 million private placement.
The private placement is expected to fully fund vTv Therapeutics' phase 3 study of cadisegliatin, a treatment for a rare disease.
The stock's significant increase has led it to become the leader of the Prism MarketView Public Health index, outperforming other stocks in the sector.

Generated by AI

News

H.C. Wainwright Sticks to Its Buy Rating for vTv Therapeutics (VTVT)

Detailed price information for Vtv Theraptcs Cl A (VTVT-Q) from The Globe and Mail including charting and trades.

7d agoThe Globe and Mail

vTv Therapeutics at H.C. Wainwright conference: CADI advances

13d agoInvesting.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HIGH POINT, N.C., Sept. 15, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 2,500 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment in accordance with Nasdaq Listing Rule

14d agoYahoo Finance

Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT)

Detailed price information for Kymera Therapeutics Inc (KYMR-Q) from The Globe and Mail including charting and trades.

26d agoThe Globe and Mail

vTv Therapeutics to Participate in September Investor Conferences

HIGH POINT, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that management will participate in the following investor conferences in September: H.C. Wainwright 28th Annual Global Investment ConferenceFormat: Fireside Chat and one-on-one investor meetingsDate: Wednesday, September 16, 2026Time: 10:00-10:30 AM ETLocation: Ne

27d agoYahoo Finance

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HIGH POINT, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 2,500 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment in accordance with Nasdaq Listing Rule 5

1mo agoYahoo Finance Singapore

Also Discussed

Investors talking about VTVT also mention

#	Name	Attention
1	Planet Green Holdings Corp.PLAG	0%new
2	MRIN - Marin Software Incorporated	——
3	IGC Pharma Inc.IGC	0.01%+0
4	Oragenics Inc.OGEN	0%0
5	Avalon Holdings Corp. Class A Common StockAWX	0%new
6	Adial Pharmaceuticals, Inc.ADIL	0%0
7	CREG - Smart Powerr Corp.	——
8	RHE - Regional Health Properties, Inc.	——
9	Bio-Path Holdings Inc.BPTH	0%0
10	Arcadia Biosciences Inc.RKDA	0.01%0

vTv Therapeutics Inc. Class A Common Stock

Healthcare
Biotechnology

vTv Therapeutics Inc. Class A Common Stock represents equity in vTv Therapeutics, a late-stage biopharmaceutical company focused on developing oral small-molecule therapies for diabetes and other chronic diseases. The company’s current pipeline centers on treatments designed to address metabolic and inflammatory conditions, with particular emphasis on diabetes-related programs and other areas of unmet medical need. vTv Therapeutics works primarily through the discovery and clinical development of drug candidates intended for oral administration, a format that supports convenient long-term use in chronic disease care. Its business is concentrated on advancing proprietary therapeutic programs rather than commercial product sales, making the company a development-stage participant in the biotechnology sector. vTv Therapeutics is headquartered in High Point, North Carolina, and its Class A common stock is its primary public equity class.

Website

Location

3980 Premier Drive

High Point, NC, 27265

United States

Social

What share of all stock conversation is about VTVT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Jul 16

BTIG raises target price for VTVT to $57 from $49.
Volume is decent, but it's unclear whether the buying or selling is bullish.
The stock has been making money for some through shorting, but the lack of news is a gamble.

Generated by AI

Sentiment

Of the messages about VTVT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	94.36% -1.84
Bearish	—	—	0% 0	5.64% +1.84

Bullish· Mar 17

The low float of 1.2 million shares and strong recent news could drive $VTVT to $50.00.
$VTVT has shown a significant premarket move and strong volume increase, with a 2921% rise in volume compared to its daily average.
The stock has a strong technical setup, with a golden cross and potential for a breakout to $56, with many analysts and institutions owning a large portion of the shares.

Bearish· Jan 26

$VTVT is a potential victim of pump and dump scams, with coordinated scammers spreading fake posts to manipulate prices.
The stock's recent price action may be due to a rug pull, with the volume not supporting the alleged bull run.
$VTVT is considered a not wise investment, with many users warning against it and predicting a significant price drop.

Generated by AI

Topics

Of the messages about VTVT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	39.37%
Announcements	—	—	—	23.62%
Analysts	—	—	—	33.86%
Controversies	—	—	—	3.15%
Earnings	—	—	—	0%
Macro	—	—	—	0%

Earnings· May 10

$VTVT's earnings call is anticipated, but the exact date is not specified.
vTv Therapeutics Inc. had a mixed performance in December, but had previously surprised with three quarters of strong earnings.
vTv Therapeutics Inc.'s recent earnings have been a subject of optimism, with hopes for a strong showing in the latest report.

Analysts· Feb 18

Cantor Fitzgerald analyst Charles Duncan initiates coverage on vTv Therapeutics with an Overweight rating and a price target of $5.
The price target represents a significant premium to the current price, with a potential upside of 515.31%.
The analyst's enthusiasm is driven by vTv Therapeutics' lead candidate, ttp-399 (GK Activator), which is expected to enter Phase 3 trials soon as a potential treatment for Type-1 Diabetes.

Announcements· Mar 17

vTv Therapeutics' cadisegliatin program, including the CATT1 Phase 3 trial in type 1 diabetes, has been cleared by the FDA to resume after a clinical hold was lifted.
The hold was originally placed due to a chromatographic signal in a human absorption study, but was resolved as an experimental artifact after further investigation.
The company expects to expedite the initiation of pivotal studies for future New Drug Application submission by shortening the trial from 12 to 6 months.

Technical Analysis· Jun 1

$VTVT is building higher lows and may break $1, with a bullish trend line holding.
$VTVT has resistance near $1.05, $1.11, $1.19, $1.27, $1.37, $1.46, and $1.59, with support near $0.93, $0.85, and $0.78.
$VTVT needs to break above its vwap of $0.8337 for confirmation, and is testing a support level.

Generated by AI

Community

Of the messages about VTVT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	83.33%	71.92%
Newcomers	0%	0%	16.67%	28.08%

Regulars· Feb 28

The company vTv Therapeutics Inc. has secured a private placement of $51 million from healthcare-focused institutional investors and the JDRF T1D Fund.
This investment marks a significant milestone for the company, which has seen a notable increase in value, with a 55.2% pre-market rise.
The funds will support the company's ongoing efforts, particularly in the area of developing treatments for Type 1 diabetes.

Newcomers· Feb 28

New investors are watching $VTVT for its impressive price surge, up over 100% after announcing a $51 million private placement.
The private placement is expected to fully fund vTv Therapeutics' phase 3 study of cadisegliatin, a treatment for a rare disease.
The stock's significant increase has led it to become the leader of the Prism MarketView Public Health index, outperforming other stocks in the sector.

Generated by AI

vTv Therapeutics

Social

Jul 16

Bullish· Mar 17

Bearish· Jan 26

Earnings· May 10

Analysts· Feb 18

Announcements· Mar 17

Technical Analysis· Jun 1

Regulars· Feb 28

Newcomers· Feb 28

H.C. Wainwright Sticks to Its Buy Rating for vTv Therapeutics (VTVT)

vTv Therapeutics at H.C. Wainwright conference: CADI advances

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT)

vTv Therapeutics to Participate in September Investor Conferences

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Also Discussed

vTv Therapeutics Inc. Class A Common Stock

Company Information

Location

H.C. Wainwright Sticks to Its Buy Rating for vTv Therapeutics (VTVT)

vTv Therapeutics at H.C. Wainwright conference: CADI advances

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT)

vTv Therapeutics to Participate in September Investor Conferences

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Also Discussed

Social

Jul 16

Bullish· Mar 17

Bearish· Jan 26

Earnings· May 10

Analysts· Feb 18

Announcements· Mar 17

Technical Analysis· Jun 1

Regulars· Feb 28

Newcomers· Feb 28